Mergers & Acquisitions

Adverum Biotechnologies, Inc. (NasdaqCM: ADVM)

Contact a Lawyer Now

(855) 768-1857

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Adverum will receive $3.56 per share in cash plus one non-transferrable contingent value right (CVR) entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or fill out the form on this page.

Please note that the transaction is structured as a tender offer, such that time may be of the essence.